Turn Therapeutics (TTRX) Notes Payables (2025 - 2026)

Turn Therapeutics' (TTRX) quarterly Notes Payables came in at $2.8 million in Q1 2026, down 8.62% quarter-over-quarter from $3.0 million in Q4 2025.

Turn Therapeutics (TTRX) Notes Payables (2025 - 2026) Analysis & Trends

Turn Therapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $2.8 million for Q1 2026.

  • On a quarterly basis, Notes Payables changed N/A year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.0 million, changed N/A from the prior year.
  • Notes Payables fell to $2.8 million in Q1 2026 per TTRX's latest filing, from $3.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $3.0 million in Q4 2025 and bottomed at $2.8 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Turn Therapeutics 282.39 Mn 282.39 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 2.77 Mn
Dec 31, 2025 3.03 Mn